CoChat

Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance

Open access
De Fano, Michelantonio, Malara, Massimo, Vermigli, Cristiana, Murdolo, Giuseppe · 2024 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index; 71 of the 195 sources its claims cite were checked for support.

Abstract

Adipose tissue (AT) represents a plastic organ that can undergo significant remodeling in response to metabolic demands. With its numerous checkpoints, the incretin system seems to play a significant role in controlling glucose homeostasis and energy balance. The importance of the incretin hormones, namely the glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic peptide (GIP), in controlling the function of adipose cells has been brought to light by recent studies. Notably, a “paradigm shift” in reevaluating the role of the incretin system in AT as a potential target to treat obesity-linked metabolic disorders resulted from the demonstration that a disruption of the GIP and GLP-1 signaling axis in fat is associated with adiposity-induced insulin-resistance (IR) and/or type 2 diabetes mellitus (T2D). We will briefly discuss the (patho)physiological functions of GLP-1 and GIP signaling in AT in this review, emphasizing their potential impacts on lipid storage, adipogenesis, glucose metabolism and inflammation. We will also address the conundrum with the perturbation of the incretin axis in white or brown fat tissue and the emergence of metabolic disorders. In order to reduce or avoid adiposity-related metabolic complications, we will finally go over a potential scientific rationale for suggesting AT as a novel target for GLP-1 and GIP receptor agonists and co-agonists.

Overview

CoChat Summary

TL;DR

This narrative review argues that adipose tissue is a direct target of the incretin axis, proposing that disrupted GLP-1 and GIP signaling in fat contributes to obesity-linked insulin resistance and type 2 diabetes. It synthesizes receptor-expression, mechanistic, and clinical evidence to support repositioning adipose tissue as a therapeutic target for incretin-based drugs and co-agonists.

Key findings

  • GLP-1 receptors are expressed in both mature adipocytes and the stromal vascular fraction of human adipose tissue; GLP-1R expression in visceral fat is up-regulated in morbid obesity with a high degree of insulin resistance, while subcutaneous expression does not differ by IR degree, suggesting a possible compensatory mechanism.
  • GLP-1 has dose-dependent, opposing effects on adipocytes: lipogenic action predominates at picomolar concentrations and lipolytic action at nanomolar doses; GLP-1 also promotes pre-adipocyte differentiation, inhibits apoptosis, and increases insulin-dependent glucose uptake via GLUT4 up-regulation.
  • GIP receptors are present on fat cells; GIP facilitates glucose uptake, lipoprotein lipase activity and lipogenesis, and GIP-R expression increases with adipocyte differentiation. GIP-R expression is down-regulated in subcutaneous adipose tissue of obese individuals and negatively associated with BMI, waist circumference, systolic blood pressure, glucose and TAG values.
  • A meta-analysis of 10 trials found GLP-1 RA treatment reduced visceral adipose tissue by 11.2% versus 8.3% for subcutaneous adipose tissue in patients with T2D.
  • Weight loss with GLP-1 RAs is more pronounced in females than males; women had 32% higher liraglutide exposure than men at similar weights, and GI adverse events (more common in females) are associated with greater weight reduction.
  • Human studies of liraglutide (1.8 mg/day, 26 weeks) and exenatide found no significant reduction in supraclavicular brown adipose tissue fat fraction, and REE was reduced or unchanged.

Methods

  • Narrative review; no primary data collection or systematic search protocol is described.
  • Synthesizes preclinical (cell culture, rodent) and human evidence on GLP-1/GIP receptor expression and action in white, brown and beige adipose tissue, plus clinical trial and meta-analytic data on GLP-1 RA effects on fat depots, sex differences, and cancer risk.
  • Includes discussion of incretin signaling mechanisms (cAMP/PKA/EPAC2, ERK-1/2, β-arrestin, Gαq/PKC pathways) and hepatic, skeletal muscle and adipose actions.

Limitations

  • The paper states that molecular mechanisms of incretin action are "complex, cell-specific, and not fully understood," and that data on GLP-1 and GIP effects in skeletal muscle are "still scant" with mechanisms "basically unclear."
  • The authors note that findings on GLP-1R expression in adipose tissue are pertinent only to individuals with morbid obesity and T2D and cannot be generalized to non-morbidly obese or overweight subjects with insulin resistance; GLP-1R expression in adipose tissue was not useful for predicting diabetes remission, IR improvement or weight loss after bariatric surgery.
  • The authors state that conflicting findings on GIP actions in adipose tissue are at odds with recent clinical results and may reflect missing tools to evaluate long-term GIP-R stimulation effects; the paradoxical similar metabolic effects of GIP agonists and antagonists "remain to be resolved."
  • Evident from the text: as a narrative review without a stated systematic search strategy, selection of cited evidence is not transparently reproducible.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms25168650

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 (Panel A): Following their intestine secretion, the activation of GLP-1/GLP1-R as well as that of GIP/GIP-R in adipose precursor cells appears important to preserve adipogenesis and fat mass expansion at an “equilibrium” set point. Healthy adipose tissue expansion induces a “metabolically healthy” obese phenotype. (Panel B): The disruption of GLP1/GLP1-R and that of GIP/GIP-R sensitivity in adipose precursor cells points to a “GLP1/GIP-resistant” adipose-specific phenotype as a predisposing factor to the development of metabolically unhealthy obesity.
Figure 1 (Panel A): Following their intestine secretion, the activation of GLP-1/GLP1-R as well as that of GIP/GIP-R in adipose precursor cells appears important to preserve adipogenesis and fat mass expansion at an “equilibrium” set point. Healthy adipose tissue expansion induces a “metabolically healthy” obese phenotype. (Panel B): The disruption of GLP1/GLP1-R and that of GIP/GIP-R sensitivity in adipose precursor cells points to a “GLP1/GIP-resistant” adipose-specific phenotype as a predisposing factor to the development of metabolically unhealthy obesity.CC BY · PubMed Central
Figure 2 (Panel A): GIP «sensitive» adipocyte, GIP «sensitive» adipocyte. In mature fat cells GIP acts as an insulin-sensitizer incretin during glucose uptake by promoting and engaging, in the presence of insulin, the lipogenic machinery. (Panel B): GIP «insensitive» adipocyte. The disruption of GIP/GIP-R in fat cells leads to a breakdown of the lipogenic machinery, thus contributing to lipid overflow with gluco-lipotoxic effects.
Figure 2 (Panel A): GIP «sensitive» adipocyte, GIP «sensitive» adipocyte. In mature fat cells GIP acts as an insulin-sensitizer incretin during glucose uptake by promoting and engaging, in the presence of insulin, the lipogenic machinery. (Panel B): GIP «insensitive» adipocyte. The disruption of GIP/GIP-R in fat cells leads to a breakdown of the lipogenic machinery, thus contributing to lipid overflow with gluco-lipotoxic effects.CC BY · PubMed Central

Verification

Claims the paper makes

61 Valid · 9 Not valid · 88 Not checked · 34 Own results and interpretations

93 more claims · 50 with their cited sources checked

Create a free account to see all 192 claims and to verify the 124 references still open.

See all claims — free account
  • It may state two separate claims as one. 72
  • Probably not a substantial claim. 36

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 139 references

Research works printed but not linked: 1

  1. Finan, 2016, Reapprisal of GIP pharmacology for metabolic disease, Trends Endocrinol. Metab., 22, 359

Cited by

See all 17

Metadata

Authors
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G.
Affiliations
  • Complex Structure of Endocrinology and Metabolism, Department of Medicine, Azienda Ospedaliera Santa Maria Misericordia, Ospedale di Perugia, 06081 Perugia, Italy
  • Azienda Ospedaliera di Perugia (IT)
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2024-08-08
Volume
25
Issue
16
Pages
8650
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4401412316
Cited by
17
References
138
Citations by year
2026: 5 · 2025: 11 · 2024: 1
FWCI
1.12
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Physiology (medical) › Adipose Tissue and Metabolism
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
adipose tissue, incretin system, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, insulin resistance, obesity, type 2 diabetes, adipose tissue remodeling, adipogenesis, fat deposition, glucose metabolism, adipose tissue inflammation, brown adipose tissue, white adipose tissue, GLP-1 receptor agonists, GIP receptor agonist, energy balance
MeSH terms
Adipose Tissue, Animals, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Insulin Resistance, Obesity, Signal Transduction, Glucagon-Like Peptide 1, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance. https://app.cochat.ai/papers/10.3390/ijms25168650
The paper
De Fano, M., Malara, M., Vermigli, C., & Murdolo, G. (2024). Adipose Tissue: A Novel Target of the Incretin Axis? A Paradigm Shift in Obesity-Linked Insulin Resistance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25168650

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.